Cargando…

Label-free LC-MS analysis of HER2+ breast cancer cell line response to HER2 inhibitor treatment

BACKGROUND: Human epidermal growth-factor receptor (HER)-2 is overexpressed in 25 % of breast-cancers and is associated with an aggressive form of the disease with significantly shortened disease free and overall survival. In recent years, the use of HER2-targeted therapies, monoclonal-antibodies an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Luca, Alessio, Henry, Michael, Meleady, Paula, O’Connor, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524286/ https://www.ncbi.nlm.nih.gov/pubmed/26238995 http://dx.doi.org/10.1186/s40199-015-0120-y

Ejemplares similares

A Label-Free Quantitative Analysis for the Search of Proteomic Differences between Goat Breeds
por: Di Luca, Alessio, et al.
Publicado: (2022)

Label-free quantitative proteomics and stress responses in pigs—The case of short or long road transportation
por: Di Luca, Alessio, et al.
Publicado: (2022)

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
por: Spector, Neil, et al.
Publicado: (2007)

Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines
por: Burguin, Anna, et al.
Publicado: (2020)

Dataset of mouse hippocampus profiled by LC–MS/MS for label-free quantitation
por: English, Jane A., et al.
Publicado: (2016)

Proteome dataset of Hemileia vastatrix by LC–MS/MS label-free identification
por: Cury, Natália Faustino, et al.
Publicado: (2022)

Comparative Proteomics Analysis of Pig Muscle Exudate through Label-Free Liquid Chromatography-Mass Spectrometry
por: Di Luca, Alessio, et al.
Publicado: (2023)

PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
por: McDermott, Martina SJ, et al.
Publicado: (2014)

(131)I-Labeled Anti-HER2 Nanobody for Targeted Radionuclide Therapy of HER2-Positive Breast Cancer
por: Zhao, Lingzhou, et al.
Publicado: (2023)

Label-Free Virtual HER2 Immunohistochemical Staining of Breast Tissue using Deep Learning
por: Bai, Bijie, et al.
Publicado: (2022)

Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors
por: Floros, Konstantinos V., et al.
Publicado: (2021)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

Correction: Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines
Publicado: (2020)

Antitumor activity of pan‐HER inhibitors in HER2‐positive gastric cancer
por: Yoshioka, Takahiro, et al.
Publicado: (2018)

Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
por: McDermott, Martina S. J., et al.
Publicado: (2023)

The History and Development of HER2 Inhibitors
por: Xia, Xiaohui, et al.
Publicado: (2023)

Ebselen oxide and derivatives are new allosteric HER2 inhibitors for HER2‐positive cancers
por: Blasquez, Lucas, et al.
Publicado: (2023)

Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes
por: Watson, Spencer S., et al.
Publicado: (2018)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Normalization and missing value imputation for label-free LC-MS analysis
por: Karpievitch, Yuliya V, et al.
Publicado: (2012)

Comparative docking analysis of tyrosine kinase inhibitors with HER2 and HER4 receptors
por: Sonar, Priyanka, et al.
Publicado: (2022)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

Comparative Label-Free Liquid Chromatography–Mass Spectrometry Milk Proteomic Profiles Highlight Putative Differences between the Autochthon Teramana and Saanen Goat Breeds
por: Di Luca, Alessio, et al.
Publicado: (2023)

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
por: Collins, Denis M., et al.
Publicado: (2019)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

HER-3 expression in HER-2-amplified breast carcinoma
por: Czopek, Jacek, et al.
Publicado: (2013)

HER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric adenocarcinoma
por: Liu, Zimin, et al.
Publicado: (2021)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

Discovery of a Potential HER2 Inhibitor from Natural Products for the Treatment of HER2-Positive Breast Cancer
por: Li, Jianzong, et al.
Publicado: (2016)

A New Strategy for Early Diagnosis of Type 2 Diabetes by Standard-Free, Label-Free LC-MS/MS Quantification of Glycated Peptides
por: Zhang, Mei, et al.
Publicado: (2013)

Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
por: Stenehjem, David D, et al.
Publicado: (2014)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
por: Tarantino, P., et al.
Publicado: (2023)

Improving HER2 testing reproducibility in HER2-low breast cancer
por: Sajjadi, Elham, et al.
Publicado: (2022)

HER2/positive and HER2/low in inflammatory breast cancer recurrence
por: Movchan, Oleksii Volodimirovich, et al.
Publicado: (2022)

Targeting HER2-positive gastric cancer with a novel (18)F-labeled Z(HER2:342) probe
por: Pan, Yunyun, et al.
Publicado: (2019)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
por: Wu, Zihong, et al.
Publicado: (2023)

Improved Label-Free LC-MS Analysis by Wavelet-Based Noise Rejection
por: Cappadona, Salvatore, et al.
Publicado: (2010)

A label-free LC/MS-based enzymatic activity assay for the detection of PDE5A inhibitors
por: Ma, Yufeng, et al.
Publicado: (2023)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
por: Morsberger, Laura, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9m4pvogofsiutf1qvvv9kpk74p